Catalyst Funds Management’s PTC Therapeutics PTCT Stock Holding History

Catalyst Funds Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,200	Closed	-$763K	–	836
2026 Q1	$763K	Buy	11,200 +3,900	+53%	+$276K	0.13%	188
2025 Q4	$555K	Hold	7,300	–	–	0.13%	163
2025 Q3	$448K	Hold	7,300	–	–	0.07%	256
2025 Q2	$357K	Buy	+7,300	New	+$347K	0.1%	246
2024 Q2	–	Sell	-3,000	Closed	-$87.3K	–	1508
2024 Q1	$87.3K	Buy	+3,000	New	+$84K	0.02%	427

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Catalyst Funds Management's PTCT Position: Q2 2026 in Review

Catalyst Funds Management sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 11,200 shares — an estimated $763K sold.

Catalyst Funds Management first reported a position in PTCT in Q1 2024 and held it in 5 quarters. The position peaked at $763K in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Catalyst Funds Management reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
Catalyst Funds Management sold 11,200 PTC Therapeutics shares in Q2 2026, an estimated $763K.
Catalyst Funds Management first reported a position in PTC Therapeutics in Q1 2024 and held it in 5 quarters.
Catalyst Funds Management's PTC Therapeutics position peaked at $763K in Q1 2026.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.